



## **Joint Statement on Re-introduction of Hospital and Office-based Procedures in the COVID-19 Climate for the Practicing Urogynecologist and Gynecologist\***

**Keywords: COVID-19, triage, prioritization, surgical acuity, pandemic, elective surgery**

**Issued: 04/28/20 by SGS**

Traditionally, surgical procedure prioritization depends on illness acuity and resource availability after shared decision making with patients. During an emergency such as the COVID-19 pandemic, decisions must take into consideration new influences on the safety of benign gynecologic procedures. Prioritization of patients must be fluid as the pandemic waxes and wanes and is likely different in the peaks than the troughs of infection incidence. At the peak of the infectious curve, all surgeries except those that are a threat to life or limb are cancelled, as the risk to individuals coming out of self-isolation is high and could overwhelm already taxed health care resources. The trough represents a new normal, where the risk of COVID-19 infection still remains, but at a diminished rate. In the trough, the risk of infection to individuals scheduled for surgery must be weighed against the morbidity of their benign condition. In this scenario, patients with severe comorbidities, or those who would require rehabilitation or a skilled nursing facility after surgery should likely be delayed until a vaccine or effective therapy is available. Between peak and trough, the decision to proceed with surgery lies in between the two extremes. In the deceleration phase, liberalizing restrictions should start with individuals with urgent conditions who are severely affected by their gynecologic condition, weighed against their underlying health condition. How to prioritize surgeries, weighed against the risk to patients of undergoing surgery during a pandemic, has necessitated the development of tiered systems that can adapt to quickly changing environments.

The American College of Surgeons (ACS) developed several tiered ranking systems for prioritization of surgeries.

(1,2) The first scale outlines how an institution should prioritize staffing and utilization of resources and ranges from

“Alert” to “Condition Zero” based on the number of patients with COVID-19 who are admitted to the hospital. The second scale is the “Elective Surgery Acuity Scale”. This is a tiered scale ranging from 1-3; the first tier are elective surgeries, the middle tier are urgent surgeries, and the third tier are emergency surgeries. Each tier is further dichotomized into patients with and without significant comorbidities. Similar to the ACS tiered response, Goldberg et al, described a tiered system ranging from “0”, emergency surgeries and outpatient procedures that should be performed at the peak of the curve to “4”, non-essential surgeries that can be delayed until the threat of infection has subsided for urologic procedures.(3) In addition, there has been a publication by Weber LeBrun et al. that outlines the initial response to the COVID pandemic, but does not follow the ACS tier system.(4)

We have adapted the ACS tiered ranking list to develop guidance for urogynecologic and benign gynecologic surgeons. (Figure 1) The system is meant to help surgeons and their health care systems decide who should go to the operating room as the pandemic unfolds and does not list all elective surgeries in each tier. This guidance is not meant as a substitute for clinical judgement of an individual surgeon and the process of shared decision making with patients. This is particularly important for women with medical comorbidities in whom increased exposure to infected individuals outside the home outweighs the urgency of their gynecologic condition. Continued use of telemedicine to address symptom management while surgery is delayed may be helpful.

In addition, we have applied the tiered system to outpatient procedures. (Figure 2) All decisions should be made in the context of local and state directives. Many places across the globe have been in the “Condition Zero” level of planning where all but emergency surgeries are cancelled, regardless of the prevalence of COVID-19 cases in a specific area. As we approach reopening surgical services to women with non-emergent surgical problems, a new calculus is needed. The tiered system must take into account the patient’s gynecologic condition, as well as their medical comorbidities, and be able to adapt to changing conditions, as we re-open, and re-close, gynecologic surgery services for women through the pandemic. Local disease prevalence and reopening strategies may supersede this document and we defer to clinical decision making in coordination with other local resource considerations.

**Figure 1: Modified Elective Surgery Acuity Scale (mESAS) for Benign Gynecologic Indications and Surgeries**

| Tier     | Definition   | Benign Examples   | Urogyn Examples  | Suggested Location  |
|----------|--|---|--|---|
| Tier 1a  | <p><b>Low acuity surgery/healthy patient</b><br/>                     Outpatient surgery<br/>                     Not life-threatening illness</p>           | <ul style="list-style-type: none"> <li>- Benign appearing adnexal mass, asymptomatic</li> <li>- Hysterectomy, without anemia, stable symptoms</li> <li>- Myomectomy, asymptomatic</li> <li>- Hysteroscopic metroplasty</li> <li>- Endometriosis, stable symptoms</li> <li>-Chronic pelvic pain requiring diagnosis (i.e. diagnostic laparoscopy)</li> <li>-AUB, without anemia, low suspicion malignancy</li> <li>-Bleeding requiring diagnosis (i.e. diagnostic/operative hysteroscopy)</li> <li>-Persistent PMB, low suspicion (neg EMB)</li> </ul> | <ul style="list-style-type: none"> <li>-Stress urinary incontinence surgery</li> <li>-Transvaginal native tissue prolapse surgery</li> <li>- Laparoscopic prolapse repair, sacrocolpopexy</li> <li>-Asymptomatic mesh exposure</li> <li>-Neuromodulation for urinary urgency incontinence, retention or fecal incontinence</li> <li>-Diverticulectomy</li> </ul> | Outpatient<br>ASC, or<br>Hospital                                       |
| Tier 1b* | <p><b>Low acuity surgery/unhealthy patient based on ASA or Charlson comorbidity index</b></p>  |   |  | ASC or<br>hospital  |
| Tier 2a  | <p><b>Intermediate acuity surgery/healthy patient</b><br/>                     Not life threatening but potential for near future morbidity or mortality</p> | <ul style="list-style-type: none"> <li>-AUB with secondary anemia, stable</li> <li>-AUB age &gt; 50y with inability to sample in office</li> <li>-Endometriosis, poorly controlled pain or fertility desired, low AMH/ovarian reserve</li> <li>-Endometrial polyps age &gt; 50y</li> <li>- Symptomatic ovarian cyst</li> <li>- Myomectomy, symptomatic fibroid</li> </ul>   | <ul style="list-style-type: none"> <li>-Fistula repair</li> <li>-Mesh-related complication (infection or severe pain)</li> </ul>   | Outpatient or<br>overnight<br>hospitalization<br><br>ASC or<br>Hospital |
| Tier 2b* | <p><b>Intermediate acuity surgery/unhealthy patient</b></p>  |   |  | ASC or<br>hospital  |

|                 |  |  |   |  |
|-----------------|--|--|---|--|
| <b>Tier 3a</b>  | <p><b>High acuity surgery/healthy patient</b><br/>High potential for near future morbidity or mortality<br/>Severe impairment of QoL</p> | <ul style="list-style-type: none"> <li>-Endometrial hyperplasia/EIN, highly suspicious for atypia/malignancy</li> <li>-Adnexal mass, complex, suspicious for malignancy</li> <li>-AUB, secondary anemia, unstable, worsening bleeding</li> <li>-Deeply infiltrating endometriosis with severe bowel/bladder symptoms, intractable/severe pain</li> <li>- CIN II, CIN III treatment</li> <li>-Symptomatic ovarian cyst, intractable, severe pain</li> <li>- Large fibroids, with hydronephrosis, debilitating pain, bulk symptoms or urinary retention</li> <li>-Other potential GYN malignancy cases</li> <li>-Sterilization procedures for women who are not LARC candidates</li> </ul> | <ul style="list-style-type: none"> <li>- Mesh in a viscus</li> <li>- Advanced stage prolapse with evidence of upper tract obstruction and unable to retain pessary</li> <li>- Obstructed voiding after MUS</li> <li>-incarcerated prolapse</li> </ul> | <p>Outpatient hospital with pathologist available</p> <p>ASC rare but possible</p> |
| <b>Tier 3b*</b> | <p><b>High acuity surgery/unhealthy patient</b></p>  |  |   | <p>Hospital in-patient</p>   |
| <b>Tier 4a</b>  | <p><b>Emergency Surgery/healthy patient</b></p>  | <ul style="list-style-type: none"> <li>-Ruptured ectopic with hemodynamic instability</li> <li>-Hemorrhage from SAB, incomplete</li> <li>-Ruptured TOA</li> <li>-Ovarian torsion</li> <li>-Perforated viscus or complete bowel obstruction</li> <li>-Delayed postoperative hemorrhage</li> <li>-Termination of pregnancy (5)</li> <li>-Wound dehiscence</li> </ul>   |   | <p>ASC or Hospital</p>   |

\*Tier “b” indicates patients with complicated medical conditions that, in the environment of COVID-19, may place them at high risk for ICU admission and increased perioperative morbidity and mortality. This will likely affect the order of prioritization of individuals for surgery. For example, in an environment where we are just opening surgical suites, we may determine that even though the acuity of the surgical problem is high, that the tier 3b women would not go to surgery prior to the tier 2a women. On the other hand, when the risk of COVID morbidity and mortality is lower, a tier 3b woman might go ahead of tier 2a woman who is healthy. Ranking of the tiers is dependent on the COVID environment.

AMH: anti-mullerian hormone; ASC: ambulatory surgery center; AUB : abnormal uterine bleeding; CPP Chronic pelvic pain; EIN: endometrial intra-epithelial neoplasm; LARC: long-acting reversible contraception; MUS: mid-urethral sling; SIS: saline infusion sonography; SAB: spontaneous abortion; TOA: tubo-ovarian abscess; TVUS: transvaginal ultrasonography; PMB: postmenopausal bleeding; UDS: urodynamics; EMB: Endometrial biopsy

**Figure 2. Acuity Scale for Office-based Gynecologic Procedures**

| <b>Tier 1</b><br><b>Delayed beyond 12 weeks</b> |   | <b>Tier 2</b><br><b>Delayed 4 – 12 weeks</b> |   | <b>Tier 3</b><br><b>Delayed up to 4 weeks</b>                  |                          | <b>Tier 4</b><br><b>Cannot be delayed</b> |                                    |
|---|---|--|---|--|--------------------------|---|------------------------------------|
| <b>Benign GYN</b>                               | <b>UroGYN</b>                                   | <b>Benign GYN</b>                            | <b>UroGYN</b>                                   | <b>Benign GYN</b>  | <b>UroGYN</b>            | <b>Benign GYN</b>                         | <b>UroGYN</b>                      |
| Endometrial biopsy, low risk for carcinoma      | Botox, new                                      | TVUS, SIS (imaging)                          | Bulking agent, repeat<br><br>Botox, established | Endometrial biopsy, high risk for carcinoma                    | Bladder cancer follow-up | LARC insertion                            | Urethral evaluation (erosion, etc) |
| Trigger point injections for CPP, new           | Bulking agent, new                              | Office hysteroscopy                          | Non neurogenic UDS                              | Office hysteroscopy for misplaced IUD, hematometra             | Hematuria, micro         |   | Hematuria, macro                   |
|   | Stent removal and/or insertion                  | Vulvar Biopsy                                | Pessary cleaning                                | IUD insertion or replacement for non-contraceptive indications | Neurogenic UDS, new      |   | Retrograde pyelogram               |
|   | PTNS, new                                       |  | Pelvic floor physical therapy, established      | LARC replacement   | Bladder instillations    |   |                                    |
|   | Neurogenic UDS, established (not high pressure) |  |   | Colposcopy   | PTNS, established        |   |                                    |
|   |   |  |   | LEEP   |                          |   |                                    |

|  |                                    |  |  |  |  |  |                                       |
|--|------------------------------------|--|--|--|--|--|---------------------------------------|
|  | Pessary fitting                    |  |  | Trigger point injection for CPP, established |  |  | Instruction for ISC, new              |
|  | Pelvic floor physical therapy, new |  |  |  |  |  | Voiding trial, urinary retention      |
|  |                                    |  |  |  |  |  | Suprapubic catheterization, follow up |

CPP: Chronic pelvic pain; ISC: intermittent self-catheterization; IUD: intra-uterine device; LARC: Long-acting, reversible contraception; LEEP: Loop electrosurgery excision procedure; PTNS: percutaneous tibial nerve stimulation; SIS: saline infusion sonography; TVUS: transvaginal ultrasonography; UDS: urodynamics.

\* An updated Joint Statement with the addition of SRS-ASRM's position on reproductive procedures will soon follow

## References:

1. American College of Surgeons. COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures. <https://www.facs.org/covid-19/clinical-guidance/triage>. Accessed 21 April 2020.
2. Ross SW, Lauer CW, Miles WS, Green JM, Christmas AB, May AK, Matthews BD. Maximizing the calm before the storm: a tiered surgical response plan for COVID-19. Am J Coll Surg. 2020. Epub ahead of print.
3. Goldman HB, Haber, GP. Recommendations for Tiered Stratification of Urologic Surgery Urgency in the COVID-19 Era. J Urol. 2020. Epub ahead of print.
4. Weber LeBrun EE, Moawad NS, Rosenberg EI, Morey TE, Collins WO, Smulian JC. COVID-19 Pandemic: stage management of surgical services for gynecology and obstetrics. AJOG. 2020. Epub ahead of print.
5. Joint Statement on Abortion access during the COVID-19 Outbreak. ACOG, ABOG, AAGL, AGOS, ASRM, SASGOG, SFP, and SMFM. 18 March 2020. <https://www.acog.org/news/news-releases/2020/03/joint-statement-on-abortion-access-during-the-covid-19-outbreak>. Accessed 22 April 2020.